Advanced search
Publication Cover
Molecular and Cellular Biology Volume 35, 2015 - Issue 1
Submit an article Journal homepage
88
Views
61
CrossRef citations to date
0
Altmetric
Article

Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells

Huaijian Guoa Laboratory of Molecular Oncology, Clinical Research Institute of Montréal, Montréal, Québec, Canada;b Department of Medicine, McGill University, Montréal, Québec, Canada
,
Mario-Ernesto Cruz-Munoza Laboratory of Molecular Oncology, Clinical Research Institute of Montréal, Montréal, Québec, Canada;c Faculty of Medicine, University of Morelos, Cuernavaca, Mexico
,
Ning Wua Laboratory of Molecular Oncology, Clinical Research Institute of Montréal, Montréal, Québec, Canada
,
Michael Robbinsd Bristol-Myers Squibb, Princeton, New Jersey, USA
&
André Veillettea Laboratory of Molecular Oncology, Clinical Research Institute of Montréal, Montréal, Québec, Canada;b Department of Medicine, McGill University, Montréal, Québec, Canada;e Department of Medicine, University of Montréal, Montréal, Québec, CanadaCorrespondence[email protected]
Pages 41-51 | Received 31 Aug 2014, Accepted 07 Oct 2014, Published online: 20 Mar 2023

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

David Yashar, Tanya M. Spektor, Daisy Martinez, Matthew Ghermezi, Regina A. Swift, Benjamin Eades, Gary Schwartz, Shahrooz Eshaghian, Stephen Lim, Robert Vescio & James R. Berenson. (2022) A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Leukemia & Lymphoma 63:4, pages 975-983.
Read now
Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evangelos Terpos & Meletios A Dimopoulos. (2019) Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy 19:11, pages 921-928.
Read now
Klaus Podar & Martin Pecherstorfer. (2017) Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy 18:11, pages 1061-1079.
Read now
Katja Weisel. (2016) Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. OncoTargets and Therapy 9, pages 6037-6048.
Read now
Sagar Lonial, Jonathan Kaufman, Donna Reece, Maria-Victoria Mateos, Jacob Laubach & Paul Richardson. (2016) Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opinion on Biological Therapy 16:10, pages 1291-1301.
Read now
Sebastian Grosicki & Agnieszka Barchnicka. (2016) Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma. Expert Review of Hematology 9:7, pages 621-628.
Read now
María-Victoria Mateos. (2016) Elotuzumab for treating myeloma. Expert Opinion on Orphan Drugs 4:2, pages 215-222.
Read now

Articles from other publishers (54)

Pooya Farhangnia, Shamim Mollazadeh Ghomi, Shabnam Mollazadehghomi, Hamid Nickho, Mahzad Akbarpour & Ali-Akbar Delbandi. (2023) SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Yongjian Wu, Qiaohua Wang, Miao Li, Juanfeng Lao, Huishu Tang, Siqi Ming, Minhao Wu, Sitang Gong, Linhai Li, Lei Liu & Xi Huang. (2023) SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis. Journal of Clinical Investigation 133:6.
Crossref
Beverly A. Teicher & Joel Morris. (2022) Antibody-drug Conjugate Targets, Drugs, and Linkers. Current Cancer Drug Targets 22:6, pages 463-529.
Crossref
Samuel E.J. Preston, Audrey Emond, Filippa Pettersson, Daphné Dupéré-Richer, Madelyn Jean Abraham, Alberto Riva, Mena Kinal, Ryan N. Rys, Nathalie A. Johnson, Koren K. Mann, Sonia V. del Rincón, Jonathan D. Licht & Wilson H. MillerJrJr. (2022) Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. Molecular Cancer Therapeutics 21:4, pages 511-521.
Crossref
C. Christiansen, J. E. Castillo-Fernandez, A. Domingo-Relloso, W. Zhao, J. S. El-Sayed Moustafa, P.-C. Tsai, J. Maddock, K. Haack, S. A. Cole, S. L. R. Kardia, M. Molokhia, M. Suderman, C. Power, C. Relton, A. Wong, D. Kuh, A. Goodman, K. S. Small, J. A. Smith, M. Tellez-Plaza, A. Navas-Acien, G. B. Ploubidis, R. Hardy & J. T. Bell. (2021) Novel DNA methylation signatures of tobacco smoking with trans-ethnic effects. Clinical Epigenetics 13:1.
Crossref
Anna Y. Aksenova, Anna S. Zhuk, Artem G. Lada, Irina V. Zotova, Elena I. Stepchenkova, Ivan I. Kostroma, Sergey V. Gritsaev & Youri I. Pavlov. (2021) Genome Instability in Multiple Myeloma: Facts and Factors. Cancers 13:23, pages 5949.
Crossref
Alessandra Romano, Paola Storti, Valentina Marchica, Grazia Scandura, Laura Notarfranchi, Luisa Craviotto, Francesco Di Raimondo & Nicola Giuliani. (2021) Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Frontiers in Oncology 11.
Crossref
Constantine S. Mitsiades. (2021) Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. Cold Spring Harbor Perspectives in Medicine 11:7, pages a034900.
Crossref
Sophia Danhof, Leo Rasche, Anja Mottok, Tabea Steinmüller, Xiang Zhou, Martin Schreder, Teresa Kilian, Susanne Strifler, Andreas Rosenwald, Michael Hudecek, Hermann Einsele & Elena Gerhard-Hartmann. (2021) Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of Hematology 100:6, pages 1537-1546.
Crossref
Pegah Abdollahi, Maja Köhn & Magne Børset. (2021) Protein tyrosine phosphatases in multiple myeloma. Cancer Letters 501, pages 105-113.
Crossref
Amélie Cachot, Mariia Bilous, Yen-Cheng Liu, Xiaokang Li, Margaux Saillard, Mara CenerentiGeorg Alexander Rockinger, Tania Wyss, Philippe GuillaumeJulien SchmidtRaphaël Genolet, Giuseppe ErcolanoMaria Pia Protti, Walter ReithKalliopi Ioannidou, Laurence de Leval, Joseph A. TrapaniGeorge Coukos, Alexandre Harari, Daniel E. SpeiserAlexander Mathis, David Gfeller, Hatice Altug, Pedro Romero & Camilla Jandus. (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances 7:9.
Crossref
Asmi Chakraborty, Caleb Staudinger, Sandra L. King, Frances Clemente Erickson, Lee Seng Lau, Angela Bernasconi, Francis W. Luscinskas, Chad Perlyn & Charles J. Dimitroff. (2021) Galectin-9 bridges human B cells to vascular endothelium while programming regulatory pathways. Journal of Autoimmunity 117, pages 102575.
Crossref
Mariko Ishibashi, Rimpei Morita & Hideto Tamura. (2021) Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. Cancers 13:2, pages 279.
Crossref
Arjun Khunger, Erin Piazza, Sarah Warren, Thomas H. Smith, Xing Ren, Andrew White, Nathan Elliott, Alessandra Cesano, Joseph M. Beechem, John M. Kirkwood & Ahmad A. Tarhini. (2021) CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLOS ONE 16:1, pages e0245287.
Crossref
Patrick O’Connell, Sean Hyslop, Maja K. Blake, Sarah Godbehere, Andrea Amalfitano & Yasser A. Aldhamen. (2021) SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. The Journal of Immunology 206:1, pages 193-205.
Crossref
Atsushi Suzuki, Satoshi Kakugawa, Masafumi Miyoshi, Mitsuo Hori, Kenshi Suzuki, Yusuke Furukawa & Kensuke Ohta. (2020) Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia 34:11, pages 3088-3090.
Crossref
Satoko Oka, Kazuo Ono & Masaharu Nohgawa. (2019) Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone. Pathology & Oncology Research 26:3, pages 1993-1995.
Crossref
Jiro Kikuchi, Mitsuo Hori, Hidekatsu Iha, Noriko Toyama-Sorimachi, Shotaro Hagiwara, Yoshiaki Kuroda, Daisuke Koyama, Tohru Izumi, Hiroshi Yasui, Atsushi Suzuki & Yusuke Furukawa. (2019) Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia 34:1, pages 180-195.
Crossref
O’Connell, Amalfitano & Aldhamen. (2019) SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond. Vaccines 7:4, pages 184.
Crossref
Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie A. Bezman, Michael D. Robbins, Adam D. Cohen & Kerry S. Campbell. (2019) Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunology Research 7:10, pages 1633-1646.
Crossref
Patrick O’Connell, Yuliya Pepelyayeva, Maja K. Blake, Sean Hyslop, Robert B. Crawford, Michael D. Rizzo, Cristiane Pereira-Hicks, Sarah Godbehere, Linda Dale, Peter Gulick, Norbert E. Kaminski, Andrea Amalfitano & Yasser A. Aldhamen. (2019) SLAMF7 Is a Critical Negative Regulator of IFN-α–Mediated CXCL10 Production in Chronic HIV Infection. The Journal of Immunology 202:1, pages 228-238.
Crossref
Jürgen Barth. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 489 519 .
Kerry S. Campbell, Adam D. Cohen & Tatiana Pazina. (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Frontiers in Immunology 9.
Crossref
Ahmed T. Kurdi, Siobhan V. Glavey, Natalie A. Bezman, Amy Jhatakia, Jennifer L. Guerriero, Salomon Manier, Michele Moschetta, Yuji Mishima, Aldo Roccaro, Alexandre Detappe, Chia-Jen Liu, Antonio Sacco, Daisy Huynh, Yu-Tzu Tai, Michael D. Robbins, Jamil Azzi & Irene M. Ghobrial. (2018) Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics 17:7, pages 1454-1463.
Crossref
David Ritchie & Marco Colonna. (2018) Mechanisms of Action and Clinical Development of Elotuzumab. Clinical and Translational Science 11:3, pages 261-266.
Crossref
Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari & Mehdi Azad. (2018) Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. Clinical Lymphoma Myeloma and Leukemia 18:5, pages 311-320.
Crossref
Gregory Fouquet, Ingrid Marcq, Véronique Debuysscher, Jagadeesh Bayry, Amrathlal Rabbind Singh, Abderrahmane Bengrine, Eric Nguyen-Khac, Mickael Naassila & Hicham Bouhlal. (2018) Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. Oncotarget 9:22, pages 16248-16262.
Crossref
Emilia Vendelova, Diyaaeldin Ashour, Patrick Blank, Florian Erhard, Antoine-Emmanuel Saliba, Ulrich Kalinke & Manfred B. Lutz. (2018) Tolerogenic Transcriptional Signatures of Steady-State and Pathogen-Induced Dendritic Cells. Frontiers in Immunology 9.
Crossref
Massimo Offidani & Laura Corvatta. (2018) A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. Future Oncology 14:4, pages 319-329.
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele & Michael Hudecek. (2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood 130:26, pages 2838-2847.
Crossref
Saheli Sarkar, Pooja Sabhachandani, Dashnamoorthy Ravi, Sayalee Potdar, Sneha Purvey, Afshin Beheshti, Andrew M. Evens & Tania Konry. (2017) Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. Frontiers in Immunology 8.
Crossref
Josée Golay. (2017) Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. Journal of Autoimmunity 85, pages 6-19.
Crossref
James J. Driscoll & Magen Brailey. (2017) Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer and Metastasis Reviews 36:4, pages 585-598.
Crossref
Gianfranco Pittari, Luca Vago, Moreno Festuccia, Chiara Bonini, Deena Mudawi, Luisa Giaccone & Benedetto Bruno. (2017) Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Frontiers in Immunology 8.
Crossref
Daniel W. Sherbenou, Tomer M. Mark & Peter Forsberg. (2017) Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clinical Lymphoma Myeloma and Leukemia 17:9, pages 545-554.
Crossref
Natalie A. BezmanAmy JhatakiaAlper Y. KearneyTy BrenderMark MaurerKarla HenningMisty R. JenkinsAmy J. RogersPaul J. NeesonAlan J. KormanMichael D. Robbins & Robert F. Graziano. (2017) PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Advances 1:12, pages 753-765.
Crossref
Madhav V. DhodapkarIvan BorrelloAdam D. CohenEdward A. Stadtmauer. (2017) Hematologic Malignancies: Plasma Cell Disorders. American Society of Clinical Oncology Educational Book:37, pages 561-568.
Crossref
Jun Chen, Ming-Chao Zhong, Huaijian Guo, Dominique Davidson, Sabrin Mishel, Yan Lu, Inmoo Rhee, Luis-Alberto Pérez-Quintero, Shaohua Zhang, Mario-Ernesto Cruz-Munoz, Ning Wu, Donald C. Vinh, Meenal Sinha, Virginie Calderon, Clifford A. Lowell, Jayne S. Danska & André Veillette. (2017) SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544:7651, pages 493-497.
Crossref
Chaitali Passey, Johanna Mora, Robert Dodge, Leonid Gibiansky, Jennifer Sheng, Amit Roy, Akintunde Bello & Manish Gupta. (2017) An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. The AAPS Journal 19:2, pages 557-567.
Crossref
Shinsuke Iida, Hirokazu Nagai, Gen Kinoshita, Masafumi Miyoshi, Michael Robbins, Dimple Pandya, Eric Bleickardt & Takaaki Chou. (2016) Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. International Journal of Hematology 105:3, pages 326-334.
Crossref
Kejie Zhang, Aakash Desai, Dongfeng Zeng, Tiejun Gong, Peihua Lu & Michael Wang. (2016) Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 8:6, pages 10748-10759.
Crossref
María-Victoria Mateos, Miguel Granell, Albert Oriol, Joaquin Martinez-Lopez, Joan Blade, Miguel T. Hernandez, Jesus Martín, Mercedes Gironella, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Anil Singhal & Jesus San-Miguel. (2016) Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. British Journal of Haematology 175:3, pages 448-456.
Crossref
Hermann Einsele & Martin Schreder. (2016) Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Therapeutic Advances in Hematology 7:5, pages 288-301.
Crossref
Valentina Hoyos & Ivan Borrello. (2016) The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood 128:13, pages 1679-1687.
Crossref
Salma Afifi, Angela Michael & Alexander Lesokhin. (2016) Immunotherapy. Annals of Pharmacotherapy 50:7, pages 555-568.
Crossref
Yasser A. Aldhamen, David P.W. Rastall, Weimin Chen, Sergey S. Seregin, Cristiane Pereira-Hicks, Sarah Godbehere, Norbert E. Kaminski & Andrea Amalfitano. (2016) CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets. Vaccine 34:27, pages 3109-3118.
Crossref
Nadia Martinez-Martin, Sree R. Ramani, Jason A. Hackney, Irene Tom, Bernd J. Wranik, Michelle Chan, Johnny Wu, Maciej T. Paluch, Kentaro Takeda, Philip E. Hass, Hilary Clark & Lino C. Gonzalez. (2016) The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation. Nature Communications 7:1.
Crossref
Michael Low, Simona Infantino, George Grigoriadis & David Tarlinton. (2016) Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?. Immunological Reviews 270:1, pages 78-94.
Crossref
Ning Wu & André Veillette. (2016) SLAM family receptors in normal immunity and immune pathologies. Current Opinion in Immunology 38, pages 45-51.
Crossref
André Veillette, Jun Chen & Yan Lu. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology 415 423 .
Paul G Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J Jakubowiak, Marc S Raab, Thierry Facon, Ravi Vij, Darrell White, Donna E Reece, Lotfi Benboubker, Jeffrey Zonder, L Claire Tsao, Kenneth C Anderson, Eric Bleickardt, Anil K Singhal & Sagar Lonial. (2015) Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. The Lancet Haematology 2:12, pages e516-e527.
Crossref
Zhanguang Zhang, Ning Wu, Yan Lu, Dominique Davidson, Marco Colonna & André Veillette. (2015) DNAM-1 controls NK cell activation via an ITT-like motif. Journal of Experimental Medicine 212:12, pages 2165-2182.
Crossref
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesus San-Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson & Paul Richardson. (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 373:7, pages 621-631.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.